Composition for treating or preventing hyperuricemia

A kind of technology of hyperuricemia and composition, applied in the field of composition for treating or preventing hyperuricemia, and can solve problems such as gout attack

Inactive Publication Date: 2005-08-17
MARUHA
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, allopurinol is known to have side effects such as skin rash, poisoning syndrome, myelosuppression, liver damage and other systemic allergic symptoms, so it requires great caution in its use
In addition, uric acid excretion accelerators such as benzbromarone may cause gout attacks if used incorrectly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating or preventing hyperuricemia
  • Composition for treating or preventing hyperuricemia
  • Composition for treating or preventing hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0029] 7-week-old SD female rats (n=5, 10 in total) were forcibly administered intragastrically with shark-derived chondroitin sulfate protein complex (SCP: manufactured by Maruha Co., Ltd.) or distilled water (control), at a rate of 1g amount, given for 14 days. After the administration, blood was collected from the ventral aorta, serumized, and GOT, GPT, total cholesterol, HDL-cholesterol, glucose, total bilirubin, total protein, albumin, urea nitrogen, creatinine, Ca, Na, Cl, alkaline phosphatase (ALP), uric acid, a total of 15 biochemical tests. As a result, the concentration of uric acid in the SCP group was significantly lower than that in the control group (p<0.01). The results are shown in Table 1 below.

[0030] control group

[0031] n.s.: no significant difference

experiment example 2

[0033]After the domestication and feeding, 10-week-old SD female rats (n=6, 18 in total) freely ingested the following feed: the Oriental compound feed produced by Oriental Yeast Co., Ltd. contained 2.5% by mass of the total amount of induced hyperuricemia oxonate potassium (potassium oxonate) feed (inducing food), or the feed (inducing food) further contains 1.5% by mass of the total amount of chondroitin sulfate protein complex (SCP: produced by Maruha Co., Ltd. ) feed (induction + SCP food) (10-15g / day), and track the change of serum uric acid value. The experimental group was set up as "induction food group" and "induction food + SCP group", and when there was a difference in serum uric acid value between the two groups, the "induction food → induction food + SCP group" was changed from induction food to induction + SCP food , a total of 3 groups. As a result, regarding the serum uric acid value, the "inducing food group" gradually increased, while the "inducing food + SC...

experiment example 3

[0035] After the acclimatization and feeding, 4-week-old Wister male rats (n=6, 60 in total) were fed with the following feed: Oriental compound feed produced by Oriental Yeast Co., Ltd. containing 3% by mass of the total amount of induced hyperuricemia The feed (inducing food) of oxonic acid potassium salt, or the chondroitin sulfate protein complex (SCP, from salmon, SCP from cows, SCP from chickens: all were produced by Maruha Co., Ltd.) feed (10-17.5g / day), and the changes in serum uric acid value were tracked. As a result, the serum uric acid value of the four "induction+SCP" groups was significantly lower than that of the "induction food" group on the 28th day after ingesting the feed (p<0.05). The result is shown in Figure 3.

[0036] Judging from the results of the above experimental examples, the chondroitin sulfate protein complex has the effect of lowering the serum uric acid level.

[0037] The following are examples of the composition for treating or preventing ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

Description

technical field [0001] The present invention relates to a composition for treating or preventing hyperuricemia having an effect of lowering serum uric acid level. Background technique [0002] With the improvement of diet and living standards in recent years, gout has become a serious lifestyle-related disease. It is known that gout is caused by the deposition of excess uric acid produced in the body as calcium urate in the hands, fingers (toes), etc., and severe pain occurs suddenly. The treatment of gout is carried out as follows: ①Use a uric acid synthesis inhibitor to suppress the accumulation of uric acid in the body; and ②Use a uric acid excretion accelerator and a urine alkalizer to rapidly excrete the accumulated uric acid in the body. [0003] Currently, there is, for example, allopurinol as an easily available uric acid synthesis inhibitor. As uric acid excretion accelerators, probenecid, mesulfazone, and benzbromarone are known. However, allopurinol is known to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L1/30A23L1/305A23L1/308A23L13/00A23L23/00A61K35/32A61K35/56A61K35/57A61K35/58A61K35/583A61K35/60A61K35/612A61K35/618A61K35/65A61K38/00A61K38/18A61P3/00A61P7/00A61P19/06
CPCA61K31/737A23V2002/00A23L1/3085A61K31/00A23L1/3106A61K38/014A61K36/28A61K36/899A23L1/305A23L1/39A61K35/60A23L13/06A23L23/00A23L33/17A23L33/28A61P3/00A61P7/00A61P19/06A23V2250/21A23V2250/7044A23V2250/708A23V2250/612A23V2250/5108A23V2250/5422A61K2300/00A61K38/17
Inventor 室田一贵西川正纯玉井忠和吉戒和刚木原稔
Owner MARUHA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap